By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Islet Sciences 

641 Lexington Avenue, 6th Floor

New York  New York  10022  U.S.A.
Phone: 646-863-6341 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Islet Sciences Receives Notice Of Allowance For U.S. Patent Covering Novel IL-12 Inhibitors 8/6/2014 9:28:30 AM
Islet Sciences Announces Peer-Reviewed Publication Of Study Validating Novel Diabetes Diagnostic 7/16/2014 6:51:17 AM
Islet Sciences Highlights Remogliflozin Etabonate As Novel Treatment For Non-Alcoholic Steatohepatitis (NASH) 6/23/2014 7:15:48 AM
Islet Sciences To Present At The Joint Meeting Of The International Society Of Endocrinology And The Endocrine Society: ICE/ENDO 2014 6/18/2014 11:07:15 AM
Islet Sciences Presents Positive Clinical Results For Best-In-Class SGLT2 Inhibitor At American Diabetes Association Annual Meeting 6/16/2014 8:15:08 AM
Islet Sciences To Present At American Diabetes Association 6/12/2014 8:03:08 AM
Islet Sciences Appoints Steven Delmar As Chief Financial Officer 5/29/2014 6:54:53 AM
Islet Sciences Appoints William Wilkison, Ph.D. To Board Of Directors 4/21/2014 9:25:38 AM
Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results For SGLT2 Inhibitor Remogliflozin Etabonate 4/17/2014 9:22:48 AM
Islet Sciences To Acquire BHV Pharma, Inc. And Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated For Type 2 Diabetes And NASH 3/13/2014 9:13:02 AM
1234
//-->